RxDoctor Payments Data

Ashlee Russo, MD

Pulmonary Disease · Youngstown, OHNPI 1861718256

Payments from drug & device makers

$60,632in general payments, 2019–2025

Across 411 payments — averaging $147.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$28K
  • Sanofi$19K
  • Insmed, Inc.$4K
  • AstraZeneca$2K
  • United Therapeutics Corporation$2K
  • Noah Medical Corporation$2K
  • plus $4K from 33 others

What the payments were for

  • Consulting fees$3,5406%
  • Speaking & faculty fees$41,97169%
  • Travel & lodging$3,9106%
  • Food & beverage$10,89518%
  • Education$3161%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,632 in reported general payments places this provider in the 85th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$190,653
Medicare patients
518
Services billed
1,645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate23$295,300
Trelegy ElliptaFluticasone/Umeclidin/Vilanter247$211,223
Dupixent PenDupilumab40$177,125
Prolastin CAlpha-1-Proteinase Inhibitor12$143,276
NucalaMepolizumab22$81,669
Breo ElliptaFluticasone/Vilanterol195$80,281
TezspireTezepelumab-Ekko14$58,947
Breztri AerosphereBudesonide/Glycopyr/Formoterol46$31,806
Spiriva RespimatTiotropium Bromide43$26,614
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr32$22,310
Stiolto RespimatTiotropium Br/Olodaterol Hcl22$13,661
EliquisApixaban18$13,183
Fluticasone-SalmeterolFluticasone Propion/Salmeterol31$9,310
SymbicortBudesonide/Formoterol Fumarate26$8,361
Incruse ElliptaUmeclidinium Bromide27$8,301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$937$403,783523 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$362$335,57588 claims
Grifols USA, LLCProlastin C$185$143,27612 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$2,177$99,11486 claims
Teva Pharmaceuticals USA, Inc.Albuterol Sulfate$14$95622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Youngstown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →